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Streptococcus pneumoniae is a leading cause of severe bacterial infections globally. A full
understanding of the impact of pneumococcal conjugate vaccine (PCV) on pneumococcal
disease burden, following its introduction in 2009 in South Africa, can support national policy
on PCV use and assist with policy decisions elsewhere.
Methods
We developed a model to estimate the national burden of severe pneumococcal disease,
i.e. disease requiring hospitalisation, pre- (2005–2008) and post-PCV introduction (2012–
2013) in children aged 0–59 months in South Africa. We estimated case numbers for inva-
sive pneumococcal disease using data from the national laboratory-based surveillance,
adjusted for specimen-taking practices. We estimated non-bacteraemic pneumococcal
pneumonia case numbers using vaccine probe study data. To estimate pneumococcal
deaths, we applied observed case fatality ratios to estimated case numbers. Estimates
were stratified by HIV status to account for the impact of PCV and HIV-related interventions.
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We assessed how different assumptions affected estimates using a sensitivity analysis.
Bootstrapping created confidence intervals.
Results
In the pre-vaccine era, a total of approximately 107,600 (95% confidence interval [CI]
83,000–140,000) cases of severe hospitalised pneumococcal disease were estimated to
have occurred annually. Following PCV introduction and the improvement in HIV interven-
tions, 41,800 (95% CI 28,000–50,000) severe pneumococcal disease cases were estimated
in 2012–2013, a rate reduction of 1,277 cases per 100,000 child-years. Approximately 5000
(95% CI 3000–6000) pneumococcal-related annual deaths were estimated in the pre-
vaccine period and 1,900 (95% CI 1000–2500) in 2012–2013, a mortality rate difference of
61 per 100,000 child-years.
Conclusions
While a large number of hospitalisations and deaths due to pneumococcal disease still
occur among children 0–59 months in South Africa, we found a large reduction in this esti-
mate that is temporally associated with PCV introduction. In HIV-infected individuals the
scale-up of other interventions, such as improvements in HIV care, may have also contrib-
uted to the declines in pneumococcal burden.
Introduction
Streptococcus pneumoniae is a leading cause of bacterial pneumonia, meningitis, and sepsis,
and is estimated to have caused approximately 335,000 (240,000–460,000) deaths in children
aged<5 years in 2015 globally [1]. In 2008, before pneumococcal conjugate vaccines (PCVs)
were available in low-income countries, the global estimated number of pneumococcal deaths
was 541,000 (95% confidence interval [CI] 376,000–594,000) [2]. The method of estimation
differed between the pre- and post-PCV global death estimates. With regards to risk groups in
South Africa HIV-infected and HIV-exposed-uninfected children were shown to have a higher
incidence of invasive pneumococcal disease (IPD) [3] and acute lower respiratory tract infec-
tions (LRTIs) compared to HIV-unexposed-uninfected children.[4].
Prevention of pneumococcal disease by PCVs has been documented through effectiveness
and impact data from more than 50 countries [5]. In South Africa, the 7-valent pneumococcal
conjugate vaccine (PCV7) was introduced nationally in April 2009 and replaced by PCV13 in
June 2011. National surveillance data for invasive pneumococcal disease (IPD) from South
Africa showed a 69% reduction in the incidence of all-serotype IPD among children aged<2
years by 2012, with contributions by PCV and HIV-associated interventions [6].
The burden of pneumococcal disease has been described in young children in the African
region [7] with epidemiological studies in a number of countries including The Gambia [8, 9],
Kenya [10] and South Africa [11]. World Health Organization (WHO) country specific esti-
mates of disease burden [1, 7, 12] generate summed regional and global estimates using coun-
try-specific inputs for syndromic mortality (pneumonia and meningitis) along with other
country-specific parameters (e.g. pathogen specific case fatality ratios, HIV prevalence, popula-
tion size and vaccine coverage). South Africa has robust surveillance to measure IPD incidence
and thus allows for an alternative model to estimate national cases and deaths from
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pneumococcal disease, anchoring on the observed value of IPD cases. The model can be
updated over time to track improvements in health and be compared to other estimates.
We aimed to estimate the national burden of severe hospitalised pneumococcal disease
and deaths (meningitis, bacteraemic and non-bacteraemic pneumonia, and non-pneumonia
non-meningitis invasive disease) among HIV-infected and HIV-uninfected children aged
0–59 months in South Africa in two periods: 2005–2008, before PCV was introduced, and in
2012–2013, after PCV was introduced. Estimates were based on the observed IPD incidence
measures from the national GERMS-SA surveillance system, as an alternative approach to that
used by the WHO.
Methods
Data sources
GERMS-SA IPD surveillance programme. GERMS-SA is an active, national, laboratory-
based surveillance programme for IPD and other invasive organisms. All public health sector
microbiology laboratories (>200) are encouraged to submit isolates to the National Institute
for Communicable Diseases (NICD) in Johannesburg. The public sector serves 84% of the
South African population without private medical aid coverage [13]. Some private sector labo-
ratories also submit isolates. Of the public sector facilities, 24 sites have dedicated surveillance
officers who collect clinical information on identified patients thereby defining them as
enhanced sites. Laboratory-based surveillance for IPD in South Africa began in 1999 [14]; the
quality and strength of the surveillance programme was improved between 2003 and 2005.
From 2005 the quality of the surveillance system was maintained with regular checks and
audits [15]. Cases of IPD were defined as illnesses in patients with S. pneumoniae cultured
from normally sterile-body sites (e.g. cerebrospinal fluid (CSF) or blood). Information on
specimen type and age of cases is available from all sites; clinical diagnosis is reported only
from cases that occurred at enhanced sites. Severe pneumococcal disease was considered as
disease resulting in hospitalisation.
National Health Laboratory Service (NHLS) Corporate Data Warehouse (CDW). The
CDW is managed by the NHLS, the sole laboratory service provider for all public health facili-
ties in South Africa. The CDW is a repository which contains archived data on all laboratory
tests requested and results from public laboratories from 2003.
Additional input parameters for model. Values for input parameters of the model were
derived from a number of sources. For estimates of non-bacteraemic pneumococcal pneumonia
cases and adjustments for expected burden in presence of systematic blood culturing practices
we used published data from a South African PCV9 vaccine clinical trial [16, 17]. Published
data was also used to derive the CFR for non-bacteraemic pneumococcal pneumonia [18, 19].
Population denominators. Annual age-specific population denominators used to calcu-
late incidence and mortality rates were obtained from Statistics South Africa [20]. The mid-
year Statistics South Africa population estimates use the cohort-component method which is
based on knowledge of population structure, birth rates, death rates and migration as well as
assumptions of how they change. These estimates are derived from a census conducted in
2011 and are updated on an annual basis [20]. The Thembisa model, a demographic model
designed to specifically address the population impact of changing HIV interventions [21],
was used to estimate population denominators by HIV status; these denominators accounted
for the changes in mother-to-child HIV transmission rates and improvements in paediatric
antiretroviral (ARV) treatment. In this model the probability of mother-to-child transmission
was assumed to depend on the mother’s HIV disease stage, the timing of ARV therapy initia-
tion in pregnancy, the type of ARV prophylaxis received and for postnatal transmission the
Pneumococcal disease burden in children
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type of feeding. PCR testing in HIV-exposed infants was assumed to occur at birth and ARV
treatment eligibility was expanded from all children aged<1 year to all children aged 1–4
years from mid-2012 based on updated South African ARV treatment guidelines [21].
Model overview
We developed a conceptual model to estimate the national burden of pneumococcal cases, and
deaths as well as associated rates, in children aged 0–59 months in South Africa for the baseline
pre-vaccine era (an average estimate for the 2005–2008 period which had a stable disease inci-
dence [11]) and a two-year period in the post-vaccine era (2012–2013) (Fig 1; S1 and S2 Figs).
We used the observed cases of IPD hospitalisations from the GERMS-SA surveillance pro-
gramme at both time points, stratified by disease syndrome (meningitis, pneumonia and non-
pneumonia non-meningitis) and by age (<1 and 1–4 years of age) as the base rate and adjusted
for incomplete specimen collection based on Corporate Data Warehouse (CDW) data by prov-
ince among hospitalised children. Gauteng province was used as the reference province for
this adjustment because of its systematic testing practices. We stratified all estimates by HIV
status which has previously been documented to affect burden of disease [11]. Model parame-
ters are given in Table 1 and calculations are explained further below as well as shown in Fig 1
(and S1 and S2 Figs). All reported case numbers were rounded to the closest 100, except when
counts were less than 100, to reflect that case numbers were estimates and not exact numbers.
Incidence rates were calculated from the estimated cases using population denominators from
Statistics South Africa [20]; incidence rates were reported per 100,000 population without
rounding off case numbers.
Estimated number of cases and incidence rates by clinical syndrome. IPD case numbers
were estimated from national laboratory-based surveillance (described below) and divided
into fractions attributable to meningitis, bacteraemic pneumonia and non-pneumonia non-
meningitis cases on the basis of GERMS-SA clinical data. IPD case numbers were adjusted for
incomplete specimen-taking practices. A direct adjustment was not made for sensitivity of
blood culture among truly bacteraemic cases and CSF culture among those with pneumococ-
cal meningitis. We assumed that the Gauteng Province had the most complete blood culturing
practices and multiplied up the case numbers in the other provinces to calculate what the case
numbers would have been if they had had the same complete blood culturing practices as that
in Gauteng. The relevant provincial rate ratio was calculated by dividing the blood or CSF cul-
ture rate in the Gauteng Province by the rate in each individual province. To estimate the
number of cases of non-bacteraemic pneumococcal pneumonia, we extrapolated data from
PCV probe studies in South Africa [16] by using the PCV9 vaccine attributable reduction
(VAR) ratio of clinical pneumonia to bacteraemic pneumococcal pneumonia (11:1), i.e. 11
clinical cases to 1 bacteraemic case (see S1 Text for detailed methods).
Estimated number of deaths and mortality rates. Pneumococcal death estimates for
each syndrome were calculated by multiplying case estimates (as calculated above) by observed
syndrome-specific case fatality ratios (CFRs) (from GERMS-SA enhanced sites) for IPD cases
by age group and HIV status. For non-bacteraemic pneumonia parameters were taken from
two South African studies. For the 2005–2008 model period we used data from a clinical trial
conducted from 1998–2001. The CFR for clinical LRTI in HIV-uninfected children was 1.9%
(40/2139) and in HIV-infected children was 31.3% (281/899) [16]. A later case-control study
(2010–2012) for presumed bacterial pneumonia in HIV-uninfected cases showed a CFR of 1%
(13/1326) overall for cases with hospital controls (range 0.2% to 6.3% in different sites) and
<1% (2/889) for cases with community controls [22]. These CFRs were used for the 2012–
2013 model period.
Pneumococcal disease burden in children
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Fig 1. Flow diagram of the steps used to estimate the burden of invasive and non-invasive pneumococcal cases in children <5
years of age in South Africa in 2005–2008 and 2012–2013. Detailed figures are included in S1 Text. #For all syndromes total case
numbers as well as numbers stratified by HIV status were determined. ^Additional adjustment (1.89) for difference in VE estimated with
use of urinary antigen.
https://doi.org/10.1371/journal.pone.0179905.g001
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Statistical analysis
We calculated the percent reduction in incidence and death rates between the two periods
(2005–2008 and 2012–2013) using the following formulas:
% reduction in incidence rates ðIRÞ ¼
IR2005  2008   IR2012  2013
IR2005  2008
% reduction in mortality rates ðMRÞ ¼
MR2005  2008   MR2012  2013
MR2005  2008
Bootstrapping to create confidence intervals was used for all endpoints, to account for vari-
ability and uncertainty in detection rates, incidence rates and case-fatality rates from the sur-
veillance data. For each model input/adjustment factors used in the calculations we obtained
1000 bootstrapped datasets and associated estimate providing and estimated variability of each
model input/adjustment factor. This was done for either directly available data or those
obtained from the published literature. The model calculation were then repeated using each
of the 1000 bootstrapped datasets to propagate the level of variability associated with each
model input/adjustment factor. We obtained the distribution for each parameter used in the
model through resampling of the estimated parameter using the binomial distribution for pro-
portions and the Poisson distribution for count data. We used reported measures for each of
our estimates and defined the variance from 1000 resampled datasets obtained as described
above. The lower and upper limits of the 95% CI were the 2.5th and 97.5th percentile of the
1000 model values obtained from the 1000 bootstrapped datasets.
Human subjects review
Ethics approval was obtained for GERMS-SA surveillance (M081117) from the Human
Research Ethics Committee (Medical), University of the Witwatersrand, Johannesburg, South
Africa and other local hospital or provincial ethics committees, as required. Clearance for the
surveillance programme was also obtained from the U.S. Centers for Disease Control and Pre-
vention (IRB 00001223). The national surveillance programme included routine submission of
laboratory isolates to NICD with basic demographic data; this did not require patient consent
as it was part of the NICD’s national public health surveillance responsibility. At enhanced sites,
additional data from patient interviews, was collected from participants who provide written
informed consent. For children<18 years of age, written informed consent was obtained from
parents or legal guardians. All patient identifiers were removed prior to data analysis.
Sensitivity analysis
A one-way sensitivity analysis was performed by changing one variable at a time to see the
effect on the total number of cases and deaths (parameters in Table 2). A Tornado diagram
was fitted around the base case estimates for cases (S3 Fig) and deaths (S4 Fig) to evaluate the
sensitivity of the model to changes in the assumed values of key parameters (See S1 Text).
Results
Burden of invasive pneumococcal disease in the pre-vaccine era
In the pre-vaccine era (2005–2008), an estimated national average of 107,600 (83,000–140,000)
annual cases of hospitalised pneumococcal disease, corresponding to an incidence of 2,074
(1,603–2,730) per 100,000 person-years (py), occurred in children aged 0–59 months in South
Pneumococcal disease burden in children
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Table 1. Parameters used in base case model to estimate total number of cases, incidence and mortality rates for severe pneumococcal disease
among children aged <5 years in South Africa.
Parameter Value used in base case model Source of data
Number of cases of invasive pneumococcal disease for 3 clinical
syndromes (meningitis, BPP, NPNM)
IPD cases detected from enhanced and non-
enhanced surveillance sites
GERMS-SA surveillance programme
Adjustment factor for systematic blood culturing from South African
clinical trial: for Gauteng Province only
Ratio of BPP incidence (per 100,000 population) from
Soweto clinical trial (1998–1999) over the average
BPP incidence (per 100,000 population) from
GERMS-SA surveillance in the same age group from
2005–2008 (2 years of age) = 22 overall, 13 in HIV-
uninfected and 23 in HIV-infected children.
Madhi 2005: VE clinical trial
conducted in Soweto located in the
Gauteng Province
Adjustment for specimen-taking practices in provinces other than
Gauteng Province
Provincial incidence rates were adjusted by the
relative rate of blood cultures or CSF specimens
collected in each province relative to Gauteng
Province (baseline = 1). Rate ratios differed by
province and specimen type. CSF specimen province
specific rates: in 2005–2008 GA = 1.00, WC = 1.27,
KZN = 2.00, NC = 1.86, EC = 2.81, NWP = 2.48,
MP = 2.53, FS = 2.04, LP = 5.60 and in 2012–2013
GA = 1.00, WC = 0.23, KZN = 2.30, NC = 1.84,
EC = 0.85, NWP = 1.66, MP = 2.71, FS = 0.39,
LP = 5.70. Blood culture province specific rates: in
2005–2008 GA = 1.00, WC = 1.26, KZN = 6.00,
NC = 4.32, EC = 4.58, NWP = 10.51, MP = 18.06,
FS = 2.43, LP = 80.13 and in 2012–2013 GA = 1.00,
WC = 0.35, KZN = 35.35, NC = 11.82, EC = 1.61,
NWP = 15.08, MP = 40.06, FS = 10.71, LP = 82.37.
NHLS Corporate Data Warehouse
(CDW): Collates data on CSF and
blood specimens taken nationally &
submitted to NHLS laboratories
Provincial incidences rates were calculated using provincial specific
cases and provincial denominators
Rate ratio in other provinces ¼ Rate in Gauteng ProvinceRate in other provinces
Number of cases of NBP (NBP = BPP*11) Ratio of PCV9 clinical pneumonia VAR (410 cases/
100,000) to all BPP VAR (37 cases/100,000) = 11:1 –
used to calculate number of NBP cases by
multiplying ratio by BPP cases
Madhi 2005
HIV prevalence among IPD cases; used to calculate proportion of
HIV-infected and—uninfected cases.
Number of HIV-infected and—uninfected cases
calculated by syndrome and year
GERMS-SA surveillance programme
—HIV data available for enhanced
sites
Case fatality ratio CFR for bacteraemic syndromes CFR for pneumococcal bacteraemic (meningitis,
BPP, NMNP) syndromes = unadjusted
pneumococcal deaths from enhanced sites/
unadjusted pneumococcal cases from enhanced
sites; CFR determined by age, HIV status and
syndrome.
GERMS-SA surveillance data
CFR for non-bacteraemic pneumonia (2005–2008 period) CFR for clinical LRTI in HIV-uninfected
children = 1.9% (40/2139) and in HIV-infected
children = 31% (281/899).
Madhi 2005
CFR for non-bacteraemic pneumonia (2012–2013 period) CFR for presumed bacterial pneumonia in HIV-
uninfected cases = 1% (13/1326) overall for cases
with hospital controls (range 0.2% to 6.3% in different
sites) and <1% (2/889) for cases with community
controls.
Madhi 2015
Adjusted number of deaths Adjusted number of pneumococcal
deaths = CFR*Adjusted pneumococcal case
numbers
GERMS-SA surveillance data
Incidence and death rates using mid-year population denominators Incidence rates = Adjusted case numbers/population
denominator Death rates = Adjusted death numbers/
population denominator
Statistics South Africa data
HIV-specific denominators for incidence and death rates Incidence and death rates by HIV status Thembisa model (Johnson 2016)
BPP = Bacteraemic pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis; IPD = invasive pneumococcal disease; PCV9 = 9-valent
pneumococcal conjugate vaccine; VAR = Vaccine-attributable reduction; VE = vaccine efficacy; CSF = cerebrospinal fluid; NHLS = National Health
Laboratory Service; PCV13 = 13-valent PCV; CFR = case fatality ratio; NBP = Non-bacteraemic pneumococcal pneumonia
Provinces: GA = Gauteng, WC = Western Cape, KZN = KwaZulu-Natal, NC = Northern Cape, EC = Eastern Cape, NW = North West Province,
MP = Mpumalanga, FS = Free State, LP = Limpopo Province
https://doi.org/10.1371/journal.pone.0179905.t001
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Africa (Tables 3 and 4). An average of 1,100 (1,000–1,200) cases of pneumococcal meningitis
(21 per 100,000 py); 8,600 (6700–11,200) bacteraemic pneumococcal pneumonia cases (163
per 100,000 py), 93,000 (71,700–123,000) non-bacteraemic pneumococcal pneumonia cases
(1,797 per 100,000 py) and 4,900 (3,600–6,100) non-pneumonia non-meningitis invasive
pneumococcal disease cases (93 per 100,000 py) were estimated to occur annually in children
aged 0–59 months. Based on model inputs, the overall incidence for hospitalised pneumococ-
cal disease was higher amongst infants <1 year of age (4,952 per 100,000 py) than children
aged 1–4 years (1,343 per 100,000 py), a relative risk of 3.69 (95% CI 3.64–3.71); incidence was
also higher among HIV-infected children (29,159 per 100,000 py) than among HIV-uninfected
children aged 0–59 months (891 per 100,000 py), a relative risk of 33 (95% CI 30–34). Similar
trends were observed in all syndromes (Table 4).
Table 2. Parameters for sensitivity analysis for severe pneumococcal disease among children aged <5 years in South Africa.
Parameter Value used in sensitivity model Source of data
Number of cases of invasive pneumococcal
disease for 3 clinical syndromes (meningitis,
BPP, NPNM)
As for base calculations GERMS-SA surveillance
programme
Adjustment factor for systematic blood culturing
from South African clinical trial: for Gauteng
Province only
Ratio of IPD incidence from Soweto clinical trial (1998–1999) to
the average IPD incidence from GERMS-SA surveillance in same
age group from 2005–2008 (2 years of age) = 8.
Klugman 2003: VE clinical trial
conducted in Soweto located in the
Gauteng Province
Adjustment for specimen-taking practices in
provinces other than Gauteng Province
As for base calculations NHLS CDW
Number of cases of NBP (NBP = BPP*11*1.89) PCV9 Clinical pneumonia VAR = 410 cases/100,000 and all BPP
VAR = 37 cases/100,000 = ratio 11:1
Madhi 2005
Additional adjustment for vaccine probe underestimate—VE
against VT non-bacteraemic pneumonia is closer to 45% than
85% = 1.89
Bonten 2014
Number of cases of NBP (NBP = BPP*4*1.89) PCV9 WHO CXR confirmed VAR = 155 cases/100,000 and all
BPP VAR = 37 cases/100,000 = ratio 4:1 with adjustment factor
(1.89) = ratio 7.6:1
Madhi 2005
Case fatality ratio of BPP to NBP Adjusted risk ratio for death of end-point pneumonia (1.98) to the
adjusted risk ratio for ‘other infiltrates/ abnormalities’ pneumonia
(0.66) = 3:1
Enwere 2007
CFR for non-bacteraemic pneumococcal pneumonia based on
published data on difference in CFR (28.2%) between
hospitalised all-cause bacteraemic cases and non-bacteraemic
acute medical cases (5.7%) in Kenya = 5:1.
Berkley 2005
Adjusted number of deaths Adjusted number of pneumococcal deaths = CFR*Adjusted
pneumococcal case numbers—used different CFR
GERMS-SA surveillance
programme
Deaths in the community (Deaths by syndrome outside hospital/Deaths by syndrome in-
hospital)*(Deaths from GERMS-SA enhanced sites) by age,
syndrome and year
Vital statistics data from Statistics
South Africa
Mid-year population denominators for incidence
and death rates
As for base case model Statistics South Africa data
HIV-specific denominators for incidence and
death rates
As for base case model Thembisa model (Johnson 2016)
BPP = Bacteraemic pneumococcal pneumonia; NPNM = Non-pneumonia non-meningitis; IPD = invasive pneumococcal disease; PCV9 = 9-valent
pneumococcal conjugate vaccine; VAR = Vaccine-attributable reduction; VE = vaccine efficacy; CSF = cerebrospinal fluid; NHLS = National Health
Laboratory Service; PCV13 = 13-valent PCV; CFR = case fatality ratio; NBP = Non-bacteraemic pneumococcal pneumonia
Provinces: GA = Gauteng, WC = Western Cape, KZN = KwaZulu-Natal, NC = Northern Cape, EC = Eastern Cape, NW = North West Province,
MP = Mpumalanga, FS = Free State, LP = Limpopo Province
https://doi.org/10.1371/journal.pone.0179905.t002
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Pneumococcal related deaths and mortality rates in the pre-vaccine era
In the pre-vaccine period, an average of 5,000 (3,000–6,000) annual pneumococcal-related
deaths, translating into a mortality rate of 97 per 100,000 py, was estimated to have occurred in
children aged 0–59 months (Tables 5 and 6). An average of 370 (300–400) pneumococcal men-
ingitis deaths (7 per 100,000 py), 1,300 (900–2,000) bacteraemic pneumococcal pneumonia
deaths (26 per 100,000 py), 2,300 (1,500–2,500) non-bacteraemic pneumococcal pneumonia
deaths (45 per 100,000 py) and 1,000 (200–2,000) non-pneumonia non-meningitis IPD deaths
(19 per 100,000 py) were estimated per year. The overall pneumococcal mortality rate, based
on CFRs, was higher amongst infants (303 per 100,000 py) than children aged 1–4 years (45
per 100,000 py), a relative risk of 6.73 (95% CI 6.23–7.03), and also higher amongst HIV-
infected children (1,339 per 100,000 py) than amongst HIV-uninfected children aged 0–59
months (43 per 100,000 py), a relative risk of 31 (95% CI 29–32) (Table 6).
Impact of the pneumococcal conjugate vaccine and other interventions
on the burden of disease in 2012–2013
Based on inputted model parameters we estimated that in 2012–2013 there was an average of
41,800 (28,000–50,000) pneumococcal cases in children aged 0–59 months, 65,800 fewer cases
than would have been expected based on the incidence of disease observed in 2005–2008
among this age group (Table 3). The overall national annual incidence of pneumococcal dis-
ease in 2012–2013 was estimated as 797 per 100,000 py in children 0–59 months of age, a total
rate difference of 1,277 per 100,000 (62% reduction) compared with the pre-PCV period
(Table 4). The annual incidence of pneumococcal meningitis in 2012–2013 was 5 per 100,000
py in children aged 0–59 months (rate difference of 16 per 100,000, 77% reduction), 64 per
100,000 py for bacteraemic pneumococcal pneumonia (rate difference of 99 per 100,000, 65%
reduction) and 708 per 100,000 py for non-bacteraemic pneumococcal pneumonia (rate differ-
ence of 1,089 per 100,000, 61% reduction). For all syndromes incidence was highest amongst
infants and HIV-infected children as is expected based on the rates observed in the IPD
GERMS data.
Pneumococcal related deaths and mortality rates in 2012–2013
In 2012–2013 we estimated 1,900 (1,000–2,500) annual pneumococcal deaths in children aged
0–59 months, 3,100 fewer than would have been expected based on modelled pneumococcal
deaths in 2005–2008 (Table 5). The overall South African annual mortality rate for pneumo-
coccal disease in 2012–2013 was estimated at 36 per 100,000 py in children aged 0–59 months,
a rate difference of 61 per 100,000 py (63% reduction) compared with the pre-PCV years
(Table 6). The mortality rate was 6.94 (6.35–7.70) times greater in infants (111 per 100,000 py)
than in children aged 1–4 years (16 per 100,000 py). The average pneumococcal meningitis
mortality rate in 2012–2013 was 2 per 100,000 py in children aged 0–59 months, a rate differ-
ence of 5 per 100,000 (78% reduction) compared with the 2005–2008 rate; 12 per 100,000 py
for bacteraemic pneumococcal pneumonia (rate difference of 14 per 100,000, 53% reduction)
and 18 per 100,000 py for non-bacteraemic pneumococcal pneumonia (rate difference of 27
per 100,000, 60% reduction).
Sensitivity analysis
The total numbers of pneumococcal cases and deaths estimated by the model changed depend-
ing on the values of key parameters used in the model (Table 2); variations resulted in both
higher and lower estimates of cases and deaths, showing the importance of using the best
Pneumococcal disease burden in children
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estimates (S2 and S3 Tables; Tornado diagrams, S3 and S4 Figs). For the pre-vaccine estimates,
the inclusion of death estimates in the community did not change the number of cases
(109,500) and deaths (3700) significantly from our base model (107,600 cases and 5000
deaths), while variations in the CFR resulted in an increase in the estimated number of pneu-
mococcal deaths and separate HIV estimates doubled the death rates likely fully accounting
for HIV-infected rates. In the sensitivity analysis when we changed other parameters, includ-
ing the VAR NBP/BPP ratio of 7.6:1 and the adjustment factor for systematic blood culturing
the case numbers were reduced by 25% and 9% respectively. When the same parameters were
altered in estimating pneumococcal deaths, numbers were reduced by 8% and 32%. Adding an
additional adjustment to account for the lack of sensitivity of determining the VE in pneumo-
nia increased the case estimates by 83% and the death estimates by 23% as a higher proportion
of pneumonia was assumed to have been caused by the pneumococcus.
Discussion
Our South African pneumococcal disease burden model has estimated that in the pre-vaccine
era (2005–2008) an average of 107,600 (83,000–140,000) cases of severe pneumococcal disease
were experienced per year in children aged 0–59 months. In 2012–2013, 41,800 cases were esti-
mated, a 1,277 per 100,000 py rate difference. This 62% reduction in all serotype IPD com-
pared with a non-PCV period was likely due to PCV introduction as well as improvements in
HIV care and prevention. Despite the elevated relative risk of IPD in HIV-infected children,
the low HIV prevalence in children may mean that HIV prevention has a limited effect on the
reduction of pneumococcal disease at a population level. Other studies in the PCV13 era,
which compared reductions with the PCV7 period, showed a 64% (95% CI 59–68%) reduction
in all IPD in the USA in children aged<5 years [23] and in the Gambia a 55% (95% CI 30–
71%) reduction in children aged 2–23 months and 56% (95% CI 25–75%) reduction in chil-
dren aged 2–4 years [24]. In the UK in 2014/2015 in all age groups the overall incidence of
IPD, compared to the pre-PCV7 period, declined by 47%, but an increase was noted in non-
PCV13 serotypes in this period [25].
The model estimated 5,000 (3,000–6,000) annual pneumococcal deaths in children aged
0–59 months in the pre-vaccine era; this translated into a mortality rate of 97 per 100,000 py.
In children aged 0–59 months in South Africa there was an average of 61,749 annual all cause
deaths, 19,072 annual all respiratory deaths and 14,927 annual pneumonia and influenza
deaths over the 2005–2008 period based on Statistics South Africa data [26]; the estimated
pneumococcal deaths would have made up 8%, 26% and 33% of these deaths respectively. A
meta-analysis, including studies from the US, South Africa, Gambia and the Philippines,
which assessed PCV efficacy on pneumonia, concluded that approximately 21.2% of severe
clinical pneumonia and 35.8% of chest radiograph (CXR) confirmed pneumonia was attribut-
able to pneumococcal disease [7]; the clinical trial estimates included lower-valency vaccines
and the Philippines study included a lower efficacy vaccine. In 2012–2013 we estimated that an
average of 1,900 (1,000–2,500) annual pneumococcal-related deaths occurred in children aged
0–59 months, a mortality rate reduction of 61 per 100,000 py. In 2012–2013, in children <5
years there were an estimated 35,989 overall deaths, 8,720 all respiratory and 3,946 annual
pneumonia and influenza deaths per annum in South Africa, based on Statistics South Africa
data [26]; the estimated pneumococcal deaths would have contributed to 5%, 22% and 48% of
these deaths respectively. A review by Izadnegahdar, et. al. in 2013 [27] proposed that even in
the post-PCV13 period, S. pneumoniae pneumonia may still make up 44% of pneumonia
deaths due to non-PCV13 serotypes. This estimate is higher than that reported in a Child
Health Epidemiology Reference Group (CHERG) systematic review which estimated that in
Pneumococcal disease burden in children
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2011 S. pneumoniae made up 32.7% of pneumonia deaths in the African region and globally
[28].
An updated global burden model that includes a time series from 2000–2015 [1] with
annual rates, calculated a total pneumococcal death rate of 203 (164–241) per 100,000 py,
19 (16–23) per 100,000 py for pneumococcal meningitis and 166 (133–198) per 100,000 py for
pneumococcal pneumonia in children aged 1–59 months in 2008 for South Africa. When
compared with our model from the pre-PCV era which included children 0–59 months, the
point estimates for the global model were higher than all our rates; our overall rates, 97 (63–
117) per 100,000 py; pneumonia rates, 71 (45–88) per 100,000 py, and calculated meningitis
rates, 7 (6–8) per 100,000 py. In 2012–2013, our overall rates, 36 (19–58) per 100,000 py and
pneumonia rates, 30 (12–50) per 100,000 py, were still slightly lower than the South African
estimates from the global model, 70 (57–83) and 56 (45–66) per 100,000 py respectively. The
two models differed in their conceptual approach, their approach to neonatal deaths, and the
inclusion of different input parameters, including case fatality rates which likely accounts for
the difference in death rate estimates. The global disease burden model is centred on a pro-
portional mortality approach, taking as a given the all-pathogen deaths for meningitis and for
pneumonia provided by the Maternal and Child Epidemiology Estimation (MCEE) Group.
These deaths are apportioned out to pneumococcus using country specific empirical data for
meningitis and PCV clinical trial data (for pneumonia). In contrast, the South Africa specific
model used a ‘bottom-up’ approach using IPD cases from surveillance data as the anchor for
the estimates, but it used the same PCV clinical trial data for pneumonia estimates. Lastly our
model used HIV prevalence rates differently to other models; our model used HIV prevalence
rates for children identified with pneumococcal disease from our surveillance programme,
while other models usually apply community HIV prevalence rates.
Stratifying data by HIV status revealed a 47% reduction in the incidence of all serotype
pneumococcal disease in HIV-uninfected children, and a 48% reduction in HIV-infected chil-
dren aged 0–59 months based on data inputted into the model. Based on observations from
IPD trends in South Africa, and assuming that these IPD trends reflect all pneumococcal
trends, it is likely that all of the reductions in HIV-uninfected children and approximately half
of the reductions in HIV-infected children may be attributable to the vaccine [6]. In HIV-
infected children antiretroviral therapy and improvements in the prevention of mother-to-
child transmission of HIV programme, contribute to reductions in all serotypes.
Since the IPD syndromic distribution observed in 2005–2008 and in 2012–2013 drives
the case and death estimates for these two periods, any reductions by syndrome are inherently
a result of the differences observed by syndrome in the IPD cases. As a result of those differ-
ences, the model output had reductions in all syndromes between the pre- and the post-PCV
periods. Similarly reductions were greatest in infants and HIV-infected children, the latter
driven by the relative risk inputted into the model. Similarly the overall pneumococcal mortal-
ity rate, which was driven by CFRs inputted into the model, was higher amongst infants.
This study is subject to a number of limitations. First, the model is anchored on the
GERMS-SA IPD surveillance data which is primarily drawn from public sector laboratories, so
may not be representative of all sectors in South Africa; however, 84% of the population access
public health care in South Africa [13]. The surveillance programme aims to include all cases
including those detected in private laboratories however not all private sector cases may be cap-
tured. Second, a number of assumptions were made to adjust for the lack of sensitivity of
detecting cases. Although all the assumptions were based on published literature, it is possible
that some of these assumptions were not accurate. We could also not find data on all possible
model parameters, for example the relative risk of pneumococcal disease in HIV-infected chil-
dren pre- and post-ART introduction. To simplify the model some estimates, for example
Pneumococcal disease burden in children
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VARs, were used for all patients even though in reality there may be some differences by age
and HIV status. Some estimates were only available for the pre-vaccine period and were
assumed to be relevant to the post-PCV period, which may have underestimated the reduction
in disease in the post-PCV period. The variation in our estimates was shown in our sensitivity
analysis which demonstrated the wide range of results possible by varying key parameters. This
shows the importance of using best estimates for key values. Third, we only calculated the bur-
den of severe pneumococcal disease and did not include pneumococcal disease that was cared
for only in the outpatient setting. We were unable to include otitis media burden calculations
in this model due to a lack of reliable African data. A US study showed that in children<5
years of age, acute otitis media made up 74% of pneumococcal cases [29], so this burden model
is an underestimate of true pneumococcal burden. Fourth, as we used adjustment factors from
a PCV-probe study in children [16] which based the diagnosis of pneumonia on clinical and
CXR findings only, both of which have limitations in detection, we may have underestimated
the burden of non-bacteraemic pneumonia in our calculations. Fifth, we assumed similar PCV
impact across all age strata among children less than 5 years and did not account for direct or
indirect vaccine effects separately; we assumed that by using actual reported cases this would
account for different impact rates. Sixth, there was a reduction in all-cause pneumonia deaths
in South Africa over the 2005 to 2008 period [26]; for the pre-PCV death rate calculations we
assumed that rates were similar over this period and we may have therefore overestimated the
change in pneumococcal death rates when we compared the average and not the end of the
pre-vaccine period (2008) with 2012–2013. Seventh, we included neonates as part of the<1
year old age group and did not separate them out due to small case numbers and lack of spe-
cific adjustment parameters for this group only. Although the epidemiology of disease in neo-
nates differs somewhat from older children, leaving this group out may have underestimated
the total burden of disease. Eighth, rates of disease are not entirely independent of pneumococ-
cal disease and it is possible that provinces with higher rates of culture also have higher rates of
pneumococcal disease [30]. Lastly, we used bootstrapping to generate confidence intervals to
try and account for some of the uncertainty around our estimates; however some external
parameters derived from different settings and the full scope of variability may not be fully rep-
resented by our assumptions. We attempted to reduce this by including as many factors as pos-
sible in our bootstrap resampling and running 1,000 replications. It is however likely that the
confidence intervals around case count and impact estimates are narrower than in reality.
GERMS-SA IPD surveillance data demonstrated a reduction in vaccine-type IPD of around
50% among adults aged 25 to 44 years by 2012 [6]. The indirect vaccination effects were similar
in HIV-infected (40%) and HIV-uninfected (52%) adults. It would be useful to calculate simi-
lar burden estimates, as in this paper, for individuals5 years of age.
In summary, pneumococcal disease represents a major public health burden in children
aged 0–59 months in South Africa. Pneumococcal conjugate vaccination, in conjunction with
other interventions, has resulted in a significant reduction in severe pneumococcal disease
with approximately 130,000 cases and 5,000 deaths averted over a 5-year period. Although
other interventions likely contribute to reductions in pneumococcal disease it is possible that
PCV use was the major contributor to the reduction in invasive disease.
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